Chatham Capital Group, Inc. Supernus Pharmaceuticals, Inc. Transaction History

Chatham Capital Group, Inc.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Jan 31, 2020	SELL	$19.93 - $29.13 $393,238 - $574,764	-19,731 Closed	0 $0
Q3 2019 Nov 08, 2019	BUY	$25.47 - $33.37 $1,782 - $2,335	70 Added 0.36%	19,731 $542,000
Q2 2019 Jul 24, 2019	BUY	$29.96 - $38.87 $589,043 - $764,223	19,661 New	19,661 $651,000

283

60.6M

27.7K

11.3K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $2.11B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of Chatham Capital Group, Inc., based on Form 13F filings with the SEC.

Stay updated on Chatham Capital Group, Inc. with notifications on news.